RCAG
IMMU

Rehmann Capital Advisory Group’s Immunomedics Inc IMMU Stock Holding History

Rehmann Capital Advisory Group’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-136
Closed -$1.89K – 2230
2019
Q2 		$1.89K Hold
136
– – ﹤0.01% 1792
2019
Q1 		$2.61K Buy
+136
New +$2.19K ﹤0.01% 1687

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Rehmann Capital Advisory Group's IMMU Position: Q3 2019 in Review

Rehmann Capital Advisory Group sold out of Immunomedics Inc (IMMU) in Q3 2019, closing a stake of 136 shares — an estimated $1.89K sold.

Rehmann Capital Advisory Group first reported a position in IMMU in Q1 2019 and held it in 2 quarters. The position peaked at $2.61K in Q1 2019. 208 funds tracked by Wall St. Rank hold IMMU as of Q3 2019.

  • Rehmann Capital Advisory Group reported no remaining Immunomedics Inc position as of Q3 2019 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 136 Immunomedics Inc shares in Q3 2019, an estimated $1.89K.
  • Rehmann Capital Advisory Group first reported a position in Immunomedics Inc in Q1 2019 and held it in 2 quarters.
  • Rehmann Capital Advisory Group's Immunomedics Inc position peaked at $2.61K in Q1 2019.
  • 208 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.